ALVIO Stock Overview
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.12 |
52 Week High | €0.35 |
52 Week Low | €0.09 |
Beta | 1.63 |
1 Month Change | 18.20% |
3 Month Change | -13.41% |
1 Year Change | -62.12% |
3 Year Change | -83.35% |
5 Year Change | -85.55% |
Change since IPO | -99.11% |
Recent News & Updates
Recent updates
Shareholder Returns
ALVIO | FR Biotechs | FR Market | |
---|---|---|---|
7D | -5.4% | -1.8% | -0.4% |
1Y | -62.1% | -12.1% | 1.7% |
Return vs Industry: ALVIO underperformed the French Biotechs industry which returned -10.2% over the past year.
Return vs Market: ALVIO underperformed the French Market which returned 2.3% over the past year.
Price Volatility
ALVIO volatility | |
---|---|
ALVIO Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 6.8% |
Market Average Movement | 4.4% |
10% most volatile stocks in FR Market | 9.7% |
10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALVIO's share price has been volatile over the past 3 months.
Volatility Over Time: ALVIO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 39 | Shefali Agarwal | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Valerio Therapeutics Société anonyme Fundamentals Summary
ALVIO fundamental statistics | |
---|---|
Market cap | €18.21m |
Earnings (TTM) | -€19.73m |
Revenue (TTM) | €1.44m |
12.6x
P/S Ratio-0.9x
P/E RatioIs ALVIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALVIO income statement (TTM) | |
---|---|
Revenue | €1.44m |
Cost of Revenue | €491.00k |
Gross Profit | €952.00k |
Other Expenses | €20.69m |
Earnings | -€19.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 65.97% |
Net Profit Margin | -1,367.64% |
Debt/Equity Ratio | 55.3% |
How did ALVIO perform over the long term?
See historical performance and comparison